Filter By
All Years

2016/04/15

WuXi AppTec Acquires Crelux

Munich, Germany, April 15, 2016-WuXi AppTec, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that it has acquired Crelux GmbH, a leading structure based drug discovery provider based in Munich, Germany. The addition of Crelux provides augmented scientific depth and complements existing capabilities within the WuXi structure-based drug discovery platform.

Read more

2016/04/11

WuXi AppTec Lab Testing Division’s Analytical and Stability Testing Facilities Passed FDA Inspection

Shanghai, April 11, 2016 – WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced that WuXi Lab Testing Division (LTD)’s late-and commercial-stage analytical and stability testing facilities in Shanghai successfully passed an FDA inspection for GMP compliance.

Read more

2016/04/08

Juno Therapeutics and WuXi AppTec Announce New Company to Develop Novel Cell-Based Cancer Immunotherapies in China

SEATTLE and SHANGHAI– April 8, 2016 – Juno Therapeutics (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, and WuXi AppTec, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that they have started a new company in China.

Read more

2016/03/25

WuXi AppTec Launches South Korea Branch

Seoul, March 25, 2016 – WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced the opening of its branch office in Seoul, South Korea, one of the most dynamic life science innovation hubs in the Asia Pacific region.

Read more

2016/03/04

WuXi AppTec’s STA Subsidiary Opens New Campus in Changzhou

SHANGHAI, March 4, 2016 /PRNewswire/ -- WuXi AppTec Co. Ltd. (WuXi), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that its small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA) began operations ata new, fully integrated R&D and cGMP manufacturing site in Changzhou in February 2016.

Read more